RESUMO
We recently identified an erythrocyte nucleotide accumulating in end-stage renal disease as 4-pyridone-3-carboxamide ribonucleotide triphosphate (4PYTP), a nucleotide never described previously. Plasma tryptophan concentration has been previously reported to be reduced in patients in chronic renal failure that is in turn associated with elevated precursors of tryptophan metabolism, including L -kynurenine and quinolinic acid, both of which have been implicated in the neurotoxic manifestations of chronic renal failure. Here we compare mean erythrocyte 4PYTP, and plasma tryptophan concentrations, in controls and four patient groups with renal impairment (10 per group) and confirmed a reduction in plasma tryptophan in patients on dialysis that corrected with renal transplantation. We found: An inverse correlation between plasma tryptophan and red cell 4PYTP concentrations (R(2)=0.44, P<0.001) when all patients were grouped together. Restoration of both tryptophan and 4PYTP concentrations to control values was only achieved following renal transplantation. 4PYTP was absent from erythrocytes in Molybdenum cofactor (MoCF) deficiency implicating aldehyde oxidase/dehydrogenase, a Molybdenum requiring enzyme. High 4PYTP erythrocyte concentrations in adenine or hypoxanthine-phosphoribosyltransferase deficient patients in severe uremia (113 microM and 103 microM), confirmed the lack of involvement of either enzyme in 4PYTP formation. We propose that 4PYTP is formed by a novel route involving the oxidation of the intermediates of NAD turnover from quinolinic acid by aldehyde oxidase.
Assuntos
Eritrócitos/metabolismo , Falência Renal Crônica/metabolismo , Nucleotídeos/metabolismo , Triptofano/metabolismo , Cromatografia Líquida de Alta Pressão , HumanosRESUMO
We have investigated an unusual nucleotide that accumulates, with precursors, in the erythrocytes of patients in uraemia. This nucleotide is related chemically to the NAD breakdown product, N1-methyl-2-pyridone-5-carboxamide (Me2Py), found in high concentrations in the plasma of uraemic patients. Both Me2Py and the nucleotide accumulate to high concentrations in the blood during uraemia: our investigations of samples from renal out-patients have provided information on a plausible link between the two compounds.
Assuntos
Eritrócitos/metabolismo , Niacinamida/análogos & derivados , Nucleotídeos/química , Piridinas/química , Insuficiência Renal/tratamento farmacológico , Cromatografia Líquida de Alta Pressão , Cromatografia Líquida , Humanos , Rim/metabolismo , Espectrometria de Massas , Niacinamida/química , Niacinamida/farmacologia , Nucleotídeos de Pirimidina/metabolismo , Insuficiência Renal/sangue , Insuficiência Renal/urina , Fatores de Tempo , Raios Ultravioleta , Uremia/sangueRESUMO
We show that GTP concentrations rise in the erythrocytes of renal transplant recipients receiving the immunosuppressant MMF, and demonstrate that this effect is not caused by poor renal function after engraftment. We propose a model that is consistent with our observations.
Assuntos
Azatioprina/farmacologia , Inibidores Enzimáticos/farmacologia , Eritrócitos/metabolismo , Guanosina Trifosfato/metabolismo , IMP Desidrogenase/antagonistas & inibidores , Imunossupressores/farmacologia , Sítios de Ligação , Cromatografia Líquida de Alta Pressão , Creatinina/sangue , Rejeição de Enxerto , Humanos , Transplante de Rim , Fatores de Tempo , Regulação para CimaRESUMO
The pharmacological actions of lithium and magnesium have been investigated using isolated smooth muscle preparations from the rat gastrointestinal tract. Tissue contraction was evoked by means of carbachol or electrical field stimulation and the degree of inhibition of contraction caused by lithium was measured. Lithium effects were compared with those of the chemically similar ions, magnesium and calcium, by manipulation of the physiological buffer solutions. Lithium antagonism was enhanced when tissue contractile mechanisms were dependent on extracellular calcium concentration in the bathing fluid. This suggests that lithium is acting at the cell membrane by preventing calcium entry via ion channels. These results are consistent with evidence from clinical studies which indicate low cellular accumulation of lithium at therapeutic concentrations.